Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. As therapeutic response may vary based on the heterogenous clinical and molecular phenotypes, a shift towards precision medicine approaches may improve AD management. Herein we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases or therapeutic response, and current practice of biomarkers in AD.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου